Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | BMI1 | P35226 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10291339 | 0.93 | BMI1 (0.34) | MAPTBMI1TP53HDAC6PDE2A | |
| SCHEMBL10291804 | 0.91 | MAPT (0.33) | MAPTNPC1PDE2ANTRK1 | |
| SCHEMBL1708028 | 0.89 | FFAR1 (0.37) | MAPTBMI1TP53 | |
| SCHEMBL1707879 | 0.88 | MAPT (0.34) | MAPTBMI1TP53HDAC6NPC1 | |
| SCHEMBL1708122 | 0.88 | MAPT (0.33) | MAPTBMI1TP53HDAC6NPC1 | |
| SCHEMBL1707877 | 0.87 | FFAR1 (0.42) | — | |
| SCHEMBL10291384 | 0.87 | GFER (0.38) | MAPTTP53NPC1RAB9AGAA | |
| SCHEMBL1708121 | 0.86 | FFAR1 (0.35) | MAPTBMI1TP53HDAC6PDE2A | |
| SCHEMBL10291806 | 0.84 | MAPT (0.34) | MAPTNPC1PDE2ANTRK1 | |
| SCHEMBL10291805 | 0.83 | MTNR1A (0.39) | MAPTTP53NPC1RAB9APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | MAPT 4721/4885BMI1 2098/4885TP53 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.